TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38616571

Group type: EXPERIMENTAL
Intervention: Urine drug screening (UDS) based definitions for treatment success
Number of subjects: 2492
Study: 38616781

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of natalizumab
Number of subjects: 262

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of natalizumab
Number of subjects: 262
Study: 38617387

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavioural therapy (ICBT) for 12 weeks
Number of subjects: 83
Study: 38617471

Group type: EXPERIMENTAL
Intervention: Combined pre- and intra-operative nomogram
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pre-operative nomogram
Number of subjects: 327

Group type: COMPARATOR
Intervention: Conventional predictive models
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pre-operative variables (HBV-DNA level, ICG-R15, prothrombin time, CSS) and intra-operative variable (DSM)
Number of subjects: 327
Study: 38617555

Group type: EXPERIMENTAL
Intervention: Caregiver support, burden, grief, self-efficacy, depression, quality of life, and coping measures.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Caregiver concerns regarding planning for the future and prioritizing the needs of the person with DLB over their own.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Satisfaction with medical team support.
Number of subjects: 143
Study: 38617566

Group type: EXPERIMENTAL
Intervention: Physical activity (60 min treadmill walk)
Number of subjects: 200
Study: 38617588

Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Pro (WFP) implantation
Number of subjects: 1
Study: 38617599

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid plus spartalizumab 300 mg q3w
Number of subjects: 62

Group type: COMPARATOR
Intervention: Spartalizumab alone
Number of subjects: 62
Study: 38617784

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus 30 minutes before incision, followed by continuous infusion of 3.0 mg/kg/hour until 2 hours after skin closure)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 38618141

Group type: EXPERIMENTAL
Intervention: RENEW intervention (peer health-coached resilience-building energy management)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 21
Study: 38618202

Group type: EXPERIMENTAL
Intervention: GST-HG171 (150 mg) plus Ritonavir (100 mg)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study: 38618203

Group type: EXPERIMENTAL
Intervention: Camrelizumab, nedaplatin, albumin paclitaxel, and apatinib (2-3 cycles, every 14 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Camrelizumab, nedaplatin, albumin paclitaxel, and apatinib
Number of subjects: 42
Study: 38618204

Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate 4, 8, or 12 mg once daily for 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (during the 2-week single-blind placebo run-in period and 2-week single-blind placebo withdrawal period)
Number of subjects: 35
Study: 38618545

Group type: EXPERIMENTAL
Intervention: Intervention group (specific diets given orally and in writing)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (usual approach)
Number of subjects: 210
Study: 38618548

Group type: EXPERIMENTAL
Intervention: Diet-related mobile app
Number of subjects: 88
Study: 38618550

Group type: EXPERIMENTAL
Intervention: 36 g erythritol daily for 5 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 24 g xylitol daily for 5 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: No substance (control) for 5 weeks
Number of subjects: 42
Study: 38619037

Group type: EXPERIMENTAL
Intervention: Teriflunomide (14 mg adult-equivalent dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study: 38619114

Group type: EXPERIMENTAL
Intervention: Breath analysis
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: Conventional upper endoscopy
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: Ingestible cell collection device
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: General screening preferences
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: General preferences for invitation method
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: General preferences for discussion
Number of subjects: 2258
Study: 38619136

Group type: EXPERIMENTAL
Intervention: Clip anchoring (clip group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No clip anchoring (control group)
Number of subjects: 180
Study: 38619178

Group type: EXPERIMENTAL
Intervention: sirolimus gel
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 62
Study: 38619626

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Perineal stapler resection (PSR)
Number of subjects: 330
Study: 38619649

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 580

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 580
Study: 38619715

Group type: EXPERIMENTAL
Intervention: Smartphone photoplethysmography (PPG) application for screening clinical AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard laboratory testing and ABC-bleeding risk score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and frailty index calculation
Number of subjects: 0
Study: 38619713

Group type: EXPERIMENTAL
Intervention: Continuous monitoring using a wearable sensor
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Continuous monitoring
Number of subjects: 400
Study: 38619714

Group type: EXPERIMENTAL
Intervention: Heart failure (HF) defined as left ventricular ejection fraction (LVEF) < 55% or a history of HF on admission
Number of subjects: 2562

Group type: COMPARATOR
Intervention: Non-heart failure patients
Number of subjects: 2562
Study: 38619783

Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation (CA) impairment assessment using inflatable leg recovery boots
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study: 38619824

Group type: EXPERIMENTAL
Intervention: Electronic health record-based population health management intervention
Number of subjects: 1596

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1596
Study: 38619842

Group type: EXPERIMENTAL
Intervention: LLD-CBT
Number of subjects: 251

Group type: COMPARATOR
Intervention: SUI
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 251
Study: 38619854

Group type: EXPERIMENTAL
Intervention: ESC care approach
Number of subjects: 463
Study: 38620056

Group type: EXPERIMENTAL
Intervention: FlexHD prophylactic biological mesh using sublay intraperitoneal technique
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard IC
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FlexHD prophylactic biological mesh
Number of subjects: 146
Study: 38620072

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, venetoclax, and obinutuzumab
Number of subjects: 45
Study: 38620092

Group type: EXPERIMENTAL
Intervention: Targeted drugs
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Matched-pair analysis of targeted therapies vs chemoimmunotherapy
Number of subjects: 2247
Study: 38621163

Group type: EXPERIMENTAL
Intervention: Single-sex schools
Number of subjects: 34489

Group type: EXPERIMENTAL
Intervention: Boarding schools
Number of subjects: 34489

Group type: EXPERIMENTAL
Intervention: Government schools
Number of subjects: 34489
Study: 38621162

Group type: EXPERIMENTAL
Intervention: BioFire Pneumonia plus Panel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference standard culturing with antimicrobial susceptibility testing
Number of subjects: 36
Study: 38621178

Group type: EXPERIMENTAL
Intervention: Low-dose atropine (various concentrations)
Number of subjects: 0
Study: 38621393

Group type: EXPERIMENTAL
Intervention: Bictegravir (30 mg), Emtricitabine (120 mg), Tenofovir Alafenamide (15 mg) once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg) upon attaining a bodyweight of at least 25 kg
Number of subjects: 22
Study: 38621400

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus lutetium-177
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 162
Study: 38621405

Group type: EXPERIMENTAL
Intervention: Aerosol-inhaled live-attenuated Mycobacterium bovis BCG (BCG Danish strain and BCG Bulgaria strain)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intradermally administered BCG
Number of subjects: 43
Study: 38621575

Group type: EXPERIMENTAL
Intervention: Edetate disodium (EDTA) chelation therapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 38621624

Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 15 mg zinc from ≥3 months before conception (preconception, arm 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 15 mg zinc from ∼12 weeks gestation through delivery (early pregnancy, arm 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation, arm 3)
Number of subjects: 100
Study: 38621633

Group type: EXPERIMENTAL
Intervention: ADPKD individuals
Number of subjects: 20
Study: 38621793

Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: UPA 30 mg QD
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo (initial randomization)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: UPA 15 mg QD and UPA 30 mg QD
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: TEAEs
Number of subjects: 611
Study: 38621924

Group type: EXPERIMENTAL
Intervention: Yaq-001
Number of subjects: 0
Study: 38622106

Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound (TUS)
Number of subjects: 80
Study: 38622109

Group type: EXPERIMENTAL
Intervention: Peer-led symptom management intervention
Number of subjects: 173
Study: 38622330

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 or 2.0 mg monthly or as needed (HARBOR)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 or 2.0 mg as needed (READ-3)
Number of subjects: 173
Study: 38622334

Group type: EXPERIMENTAL
Intervention: CCEF group (biophysical stimulation with a CCEF device for 8 hours per day for 60 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CCEF group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 38622370

Group type: EXPERIMENTAL
Intervention: Eosinophil recovery within 6 days after surgery
Number of subjects: 274

Group type: COMPARATOR
Intervention: Eosinophil recovery requiring more than 6 days
Number of subjects: 274
Study: 38622445

Group type: EXPERIMENTAL
Intervention: PIVKA-II combined with alpha-fetoprotein (AFP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0
Study: 38622456

Group type: EXPERIMENTAL
Intervention: Pegsitacianine, administered intravenously at 1 mg/kg 24-72 hours before surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pegsitacianine
Number of subjects: 50
Study: 38622488

Group type: EXPERIMENTAL
Intervention: Lumbar Drainage (LD)
Number of subjects: 287

Group type: COMPARATOR
Intervention: External Ventricular Drainage (EVD)
Number of subjects: 287
Study: 38622520

Group type: COMPARATOR
Intervention: Standard asthma diagnostic work-up (spirometry with reversibility and BPT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: New asthma diagnostics work-up (FeNO-test as an intermediate step)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: FeNO-test
Number of subjects: 171
Study: 38622543

Group type: EXPERIMENTAL
Intervention: Home Vision Therapy Group (new near glasses with accommodative and convergence eye exercises)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prism Group (near prismatic glasses prescribed using Sheard's criterion)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Group (new near glasses and aimless eye movement exercises)
Number of subjects: 150
Study: 38622593

Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH-HA)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 441
Study: 38622608

Group type: EXPERIMENTAL
Intervention: Remote monitoring of spirometry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remote monitoring of pulse oximetry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weekly monitoring by clinical teams
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experience questionnaire for remote measurements
Number of subjects: 60
Study: 38622629

Group type: COMPARATOR
Intervention: No preheating (control group at room temperature)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Resin composite preheated once
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Resin composite preheated ten cycles
Number of subjects: 105
Study: 38622634

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) training, 10 min per day, 5 days per week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Neutral cognitive exercises (control group), 10 min per day, 5 days per week
Number of subjects: 19
Study: 38622655

Group type: EXPERIMENTAL
Intervention: Warning labels only
Number of subjects: 3518

Group type: EXPERIMENTAL
Intervention: Tax only
Number of subjects: 3518

Group type: EXPERIMENTAL
Intervention: Combined warning labels + tax
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3518
Study: 38622671

Group type: EXPERIMENTAL
Intervention: Doppler-guided intraoperative fluid replacement therapy with lactated Ringer's solution (n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unbalanced 6% hydroxyethyl starch 130/0.4 (n = 29)
Number of subjects: 60
Study: 38622729

Group type: EXPERIMENTAL
Intervention: Access to a 6-min educational video 5 days after discharge from the hospital.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No access to the educational video (Control group).
Number of subjects: 0
Study: 38622759

Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38622766

Group type: EXPERIMENTAL
Intervention: Sodium-Glucose Cotransporter 2 Inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard care)
Number of subjects: 0
Study: 38622840

Group type: EXPERIMENTAL
Intervention: Daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide, bortezomib, and dexamethasone (RVd)
Number of subjects: 0
Study: 38622879

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R-CHP for six cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 0
Study: 38622893

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 104
Study: 38623494

Group type: EXPERIMENTAL
Intervention: Home-based titration of levodopa duodenal infusions (LCIG)
Number of subjects: 12
Study: 38624067

Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 38624150

Group type: EXPERIMENTAL
Intervention: Compression Dressing (CD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Compression Dressing (Control)
Number of subjects: 0
Study: 38625480

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients
Number of subjects: 733
Study: 38625671

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 38625721

Group type: EXPERIMENTAL
Intervention: mHealth intervention for HIV risk reduction
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Previous tablet use
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Previous smartphone use
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Reporting homelessness
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Reporting unemployment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Current school enrollment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 159
Study: 38625729

Group type: EXPERIMENTAL
Intervention: In-person recruitment for patients
Number of subjects: 382

Group type: COMPARATOR
Intervention: Remote recruitment for patients (telehealth, email, telephone)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: In-person recruitment for providers
Number of subjects: 382

Group type: COMPARATOR
Intervention: Remote recruitment for providers
Number of subjects: 382
Study: 38625800

Group type: EXPERIMENTAL
Intervention: Mavacamten (CAMZYOS), dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38625912

Group type: EXPERIMENTAL
Intervention: Self-reported screening tool (NRS 2002) at home
Number of subjects: 215

Group type: COMPARATOR
Intervention: In-hospital assessments by healthcare professionals (NRS 2002)
Number of subjects: 215
Study: 38625984

Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Number of subjects: 26
Study: 38626079

Group type: EXPERIMENTAL
Intervention: PiCSO-assisted pPCI
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional pPCI
Number of subjects: 145
Study: 38626080

Group type: EXPERIMENTAL
Intervention: Short dual antiplatelet therapy (DAPT)
Number of subjects: 5232
Study: 38626161

Group type: EXPERIMENTAL
Intervention: Abnormal placentation
Number of subjects: 649

Group type: COMPARATOR
Intervention: Uterine atony
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Intraoperative blood transfusions
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Intraoperative vasopressors
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Trauma to internal organs
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Perioperative cardiac arrest
Number of subjects: 649
Study: 38626363

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target range 80-130 mg/dL)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Standard sliding scale (80-179 mg/dL)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Both interventions (intensive insulin vs standard sliding scale)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Post-thrombolysis hyperglycemia
Number of subjects: 725
Study: 38626553

Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention in Wave 1 communities
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waitlisted Wave 2 communities
Number of subjects: 67
Study: 38626807

Group type: EXPERIMENTAL
Intervention: Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound.
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Cohort 1 HRIs with familial pancreatic cancer (FPC)
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Cohort 1 HRIs with pathogenic germline variant and familial pancreatic cancer (PGV+/FPC+)
Number of subjects: 3402

Group type: COMPARATOR
Intervention: Cohort 1 HRIs with pathogenic germline variant without familial pancreatic cancer (PGV+/FPC-)
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Increasing age as a predictor
Number of subjects: 3402
Study: 38626940

Group type: EXPERIMENTAL
Intervention: EHR tools and expedited referral workflow for IDA
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 316
Study: 38626956

Group type: EXPERIMENTAL
Intervention: Radio campaign promoting responsive caregiving and opportunities for early learning during the first 3 years of life.
Number of subjects: 250000000

Group type: COMPARATOR
Intervention: Not available.
Number of subjects: 250000000
Study: 38626961

Group type: EXPERIMENTAL
Intervention: New WHO Labour Care Guide (LCG)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Historical cohort using the partograph
Number of subjects: 520
Study: 38626958

Group type: EXPERIMENTAL
Intervention: 4CMenB (Bexsero) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38626967

Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis (LVA) operation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 110
Study: 38626974

Group type: EXPERIMENTAL
Intervention: Training cohort data used to train algorithms
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Validation cohort data used to validate algorithms
Number of subjects: 5000
Study: 38626975

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 0
Study: 38626982

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV) and other respiratory viruses
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Paired serum samples for RSV antibodies
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Clinical outcomes assessment
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Readmission and all-cause mortality data collection
Number of subjects: 3000
Study: 38627035

Group type: EXPERIMENTAL
Intervention: Selinexor administered at 60 mg weekly as maintenance therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 38627114

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise (15 min daily for 4 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study: 38627137

Group type: EXPERIMENTAL
Intervention: Preoperative beta-blockers
Number of subjects: 10272